• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Disease-modifying therapies and hematological disorders: a systematic review of case reports and case series.

作者信息

Scavone Cristina, Liguori Valerio, Adungba Olusola Jephthah, Cesare Daniele Di Giulio, Sullo Maria Giuseppa, Andreone Vincenzo, Sportiello Liberata, Maniscalco Giorgia Teresa, Capuano Annalisa

机构信息

Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.

Regional Center of Pharmacovigilance and Pharmacoepidemiology of Campania Region, Naples, Italy.

出版信息

Front Neurol. 2024 Jun 18;15:1386527. doi: 10.3389/fneur.2024.1386527. eCollection 2024.

DOI:10.3389/fneur.2024.1386527
PMID:38957352
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11217193/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da1e/11217193/710f53e19a5c/fneur-15-1386527-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da1e/11217193/710f53e19a5c/fneur-15-1386527-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da1e/11217193/710f53e19a5c/fneur-15-1386527-g001.jpg

相似文献

1
Disease-modifying therapies and hematological disorders: a systematic review of case reports and case series.疾病修饰疗法与血液系统疾病：病例报告和病例系列的系统评价
Front Neurol. 2024 Jun 18;15:1386527. doi: 10.3389/fneur.2024.1386527. eCollection 2024.
2
The Effect of Disease Modifying Therapies on Disability Progression in Multiple Sclerosis: A Systematic Overview of Meta-Analyses.疾病修饰疗法对多发性硬化症残疾进展的影响：一项荟萃分析的系统综述
Front Neurol. 2019 Jan 10;9:1150. doi: 10.3389/fneur.2018.01150. eCollection 2018.
3
Temporal and spatial patterns in the prescriptions of disease-modifying therapies for multiple sclerosis. Results from the Italian Multiple Sclerosis and Related Disorders Register.多发性硬化症疾病修正治疗处方的时空模式。来自意大利多发性硬化症及相关疾病登记处的结果。
Mult Scler Relat Disord. 2024 Jul;87:105638. doi: 10.1016/j.msard.2024.105638. Epub 2024 Apr 21.
4
Knowledge mapping of disease-modifying therapy (DMT) in multiple sclerosis (MS): A bibliometrics analysis.多发性硬化症（MS）疾病修饰疗法（DMT）的知识图谱：一项文献计量学分析。
Heliyon. 2024 May 31;10(11):e31744. doi: 10.1016/j.heliyon.2024.e31744. eCollection 2024 Jun 15.
5
The long-term effects of disease modifying therapies on disability in people living with multiple sclerosis: A systematic review and meta-analysis.疾病修正疗法对多发性硬化症患者残疾的长期影响：系统评价和荟萃分析。
Mult Scler Relat Disord. 2019 Nov;36:101374. doi: 10.1016/j.msard.2019.08.016. Epub 2019 Aug 15.
6
Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.与其他用于治疗多发性硬化症的疾病修正疗法相比，奥瑞珠单抗相关的工作生产力结果。
Neurol Ther. 2021 Jun;10(1):183-196. doi: 10.1007/s40120-020-00224-1. Epub 2020 Nov 26.
7
Disease modifying therapy management of multiple sclerosis after stem cell therapies: A retrospective case series.干细胞治疗后多发性硬化症的疾病修正治疗管理：回顾性病例系列。
Mult Scler Relat Disord. 2022 Jul;63:103861. doi: 10.1016/j.msard.2022.103861. Epub 2022 May 10.
8
Long-term results of autografting persons with multiple sclerosis are better in those not exposed to prior disease-modifying therapies.在未接受过先前疾病修正治疗的多发性硬化症患者中，自体移植的长期效果更好。
Mult Scler Relat Disord. 2023 Jul;75:104744. doi: 10.1016/j.msard.2023.104744. Epub 2023 May 5.
9
Adverse psychiatric effects of disease-modifying therapies in multiple Sclerosis: A systematic review.多发性硬化症中疾病修正疗法的不良精神影响：一项系统综述。
Mult Scler Relat Disord. 2018 Nov;26:124-156. doi: 10.1016/j.msard.2018.09.008. Epub 2018 Sep 12.
10
Association Between Body Mass Index and Response to Disease-Modifying Therapies in Patients With Relapsing-Remitting Multiple Sclerosis at King Abdulaziz University Hospital: A Retrospective Study.阿卜杜勒阿齐兹国王大学医院复发缓解型多发性硬化症患者体重指数与疾病改善疗法反应之间的关联：一项回顾性研究
Cureus. 2022 Dec 19;14(12):e32695. doi: 10.7759/cureus.32695. eCollection 2022 Dec.

引用本文的文献

1
Lymphopenia associated with sphingosine 1-phosphate receptor modulators (S1PRMs) in multiple sclerosis: analysis of European pharmacovigilance data.多发性硬化症中与1-磷酸鞘氨醇受体调节剂（S1PRMs）相关的淋巴细胞减少症：欧洲药物警戒数据分析
Pharmacol Rep. 2025 Jun;77(3):775-788. doi: 10.1007/s43440-025-00725-6. Epub 2025 Apr 9.

本文引用的文献

1
Alemtuzumab-induced immune-mediated thrombotic thrombocytopenic purpura: A newly described drug-related autoimmune disease.阿仑单抗诱导的免疫介导性血栓性血小板减少性紫癜：一种新描述的药物相关自身免疫性疾病。
Br J Haematol. 2024 Apr;204(4):1459-1463. doi: 10.1111/bjh.19263. Epub 2023 Dec 19.
2
Neutropaenia complications from Ocrelizumab and Rituximab treatment.奥瑞珠单抗和利妥昔单抗治疗导致的中性粒细胞减少并发症。
Mult Scler Relat Disord. 2024 Jan;81:105147. doi: 10.1016/j.msard.2023.105147. Epub 2023 Nov 21.
3
Alemtuzumab-induced petechiae and epistaxis in a patient with relapsing-remitting multiple sclerosis: A case report.
阿仑单抗诱发的复发缓解型多发性硬化症患者瘀点和鼻出血：一例报告
Clin Case Rep. 2023 Nov 25;11(11):e8143. doi: 10.1002/ccr3.8143. eCollection 2023 Nov.
4
Natalizumab-induced thrombocytopenia: A case report.那他珠单抗诱发的血小板减少症：一例报告。
Curr J Neurol. 2022 Jan 5;21(1):64-65. doi: 10.18502/cjn.v21i1.9363.
5
Recurrence of severe symptomatic late-onset neutropenia on ocrelizumab.奥瑞珠单抗治疗后严重症状性迟发性中性粒细胞减少症复发。
Mult Scler. 2024 Jan;30(1):131-133. doi: 10.1177/13524585231206218. Epub 2023 Oct 27.
6
Rapidly Progressing Autoimmune Hemolytic Anemia in a Pediatric Patient With COVID-19.一名新冠病毒感染儿科患者的快速进展性自身免疫性溶血性贫血
Cureus. 2023 Sep 20;15(9):e45633. doi: 10.7759/cureus.45633. eCollection 2023 Sep.
7
Thrombotic Microangiopathy after a 15-year Treatment with Interferon Beta-1b in a Patient with Multiple Sclerosis: A Case Report and Review of Literature.一名多发性硬化症患者接受15年β-1b干扰素治疗后发生血栓性微血管病：病例报告及文献复习
Intern Med. 2024 Apr 15;63(8):1113-1117. doi: 10.2169/internalmedicine.1846-23. Epub 2023 Sep 1.
8
Non-late-onset neutropaenia following treatment of multiple sclerosis with ocrelizumab.奥瑞珠单抗治疗多发性硬化后无迟发性中性粒细胞减少症。
Neurologia (Engl Ed). 2023 Sep;38(7):463-466. doi: 10.1016/j.nrleng.2021.01.005.
9
Time to Change the Current Clinical Classification of Multiple Sclerosis?是时候改变目前多发性硬化症的临床分类了吗？
JAMA Neurol. 2023 Feb 1;80(2):128-130. doi: 10.1001/jamaneurol.2022.4156.
10
Thrombotic microangiopathy due to acquired complement factor I deficiency in a male receiving interferon-beta treatment for multiple sclerosis.一名接受干扰素-β治疗多发性硬化症的男性因获得性补体因子I缺乏症导致血栓性微血管病。
Br J Clin Pharmacol. 2023 May;89(5):1682-1685. doi: 10.1111/bcp.15631. Epub 2022 Dec 23.